Takeda Appoints Rhonda Pacheco as President of U.S. Business Unit

Takeda has appointed Rhonda Pacheco, former group vice president of U.S. Cardiometabolic Health at Eli Lilly, as president of Takeda’s U.S. Business Unit and a member of the Takeda Executive Team, effective September 29, 2025.

Pacheco will succeed Julie Kim, who was appointed to succeed Christophe Weber as president and Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco’s appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division.

“We are thrilled to welcome Rhonda to Takeda,” said Julie Kim and Christophe Weber. “Rhonda embodies our values, and she brings a compelling blend of strategic acumen, operational excellence and people-first leadership that aligns seamlessly with the evolving needs of our U.S. Business Unit and Takeda’s broader enterprise vision.”

Experience

Pacheco comes to Takeda from Eli Lilly where she oversaw complex portfolios in a range of leadership roles, including successful product launches, most recently its GLP-1 portfolio, and delivered strong commercial performance.

A Massachusetts native, Pacheco holds an MBA from Duke University’s Fuqua School of Business and a doctorate of pharmacy from the University of Rhode Island.

“For me, joining Takeda to lead the U.S. Business Unit is where purpose and possibility come together — a chance to reshape how we deliver breakthrough science to patients,” said Pacheco. “I’m energized to be working with such a talented team to accelerate innovation, deepen trust, and set a new standard for what patients, partners and communities can expect from Takeda.”